Present-day understanding of the architecture of the mycobacterial cell wall arises from excellent electron-microscopic studies which demonstrate alternating zones of electron density and transparency almost reminiscent of Gram-negative cell walls and clearly pointing to a substantial lipid barrier [l]. This evidence is in accord with the chemical models of the mycobacterial envelope proposed by Minnikin [Z] of a substantial lipid permeability barrier, a staggered pseudoouter membrane contributed in one-half by the meromycolate and a-chains of mycolic acids and in the other half by an assortment of free lipids with medium-chain fatty acids (e.g. the mycocerosates of the phenolic glycolipids) and shortchain fatty acids (e.g. phospholipids). This concept of a staggered pseudo-outer membrane has received credence from the recent permeability, X-ray diffraction, calorimetry and bio- 
chemical studies of Nikaido [3] . Thus the outer half of this lipid barrier and the variable glycocalyx zone beyond it contains the many extracellular polysaccharides and exotic glycolipids of mycobacteria, many of them species-specific (e.g. the glycopeptidolipids of the Mycobactenum avium complex; the acyltrehalose-containing lipo-oligosaccharides of Mycobacterium kansasii, etc.; the phenolic glycolipids; etc.), and the inner half is comprised of the mycolic acids anchored to the rest of the cell wall core to form the mycolylarabinogalactan peptidoglycan complex [ 31.
The nature of the covalent attachment of mycolic acids to the rest of the cell wall skeleton and the detailed chemistry of the cell wall skeleton itself have been fully defined by us and others [4] . The and consists of chains of about 27 Araf units, mostly 5-linked with some 3-linked internal branching. Three such chains are attached to a linear galactan, which itself is composed of alternating 5-and 6-linked Galf units [4] . A key development in understanding the nature of the attachment between the mycolylarabinogalactan and peptidoglycan was the recognition of a special linkage unit, -L-Rhap-( 1 -,3)-~-GlcNAc-P-, joining the reducing end of the galactan to the 6-position of some of the muramic acids of peptidoglycan [3, 4] (Figure 2) .
Biosynthesis of the arabinogalactan (AG) linkage unit
Synthesis of the linkage unit In view of the role of the mycobacterial linkage unit as the fulcrum of cell wall integrity and as a potential singular site for target-directed chemotherapy against tuberculosis, we set about elucidating its biosynthesis in the belief that such information will give rise to assays amenable to high-throughput screening for new growth inhibitors of Mycobacterium tuberculosis. Initial synthesis of the linker unit takes place on a lipid carrier. We have demonstrated the following conversions:
UDP-GlcNAc + polyprenol-P (probably Cso-P) +GlcNAc-P-P-polyprenol (glycolipid 1) + UMP dTDP-Rha + GlcNAc-P-P-polyprenol-, RhaGlcNAc-P-P-polyprenol (GL-2) + dTDP UDP-Galp (via UDP-Galf) + Rha-GlcNAc-P-P-polyprenol -,Galf-Rha-GlcNAc-P-Ppolyprenol (GL-3) + UDP nUDP-Galp (via UDP-Galf) + Galf-RhaGlcNAc-P-P-polyprenol-, (Galf),-RhaGlcNAc-P-P-polyprenol (GL-4, GL-5, 
Biogenesis of the linkage unit-galactan
We have also demonstrated [5] that cell membranes of Mycobacterium smegmatis can catalyse the incorporation of [14C]Gal from UDP-["C] Galp into the glycolipid intermediates GL 3-5 and that the Gal units in GL 3-5 are Gay.
Thus conventionally prepared membranes apparently contain sufficient amounts of the enzyme UDP-galactopyranose mutase to convert UDP-Galp into UDP-Galf, to provide the Galf transferase(s) with sufficient quantities of the UDP-Galf donor. However, thoroughly washed mycobacterial membranes are inefficient at incorporating [14C]Gal from UDP-[14C]Galp into GL 3-5. Addition of the cloned UDP-galactopyranose mutase from Escherichia coli [6] allowed a very effective conversion. Recently we have demonstrated that a series of more polar [ 14C] Gal-containing glycolipids are also synthesized by the system and also a water-soluble mild-acid-labile polyprenol-P-based polymer, which apparently contains the fully extended galactan and portions of the attached arabinans, i.e. polyprenol-P-GlcNAc-Rha-(Galf ) 31-(Araf ) 5 .
Further proof that such a polymer intermediate is involved in cell wall synthesis arose from methylation analysis of the water-soluble polymerized product arising from reaction mixtures. Methylation, hydrolysis and radiochromatography of the polymer demonstrated the presence of about equal quantities of 5-and 6-linked D-Galf in addition to some 5,6-linked D-Galf, indicating that the final polyprenol-P-P-linked polymer also contained some D-Araf units.
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Biosynthetic origin of o-arabinan
Previously, in conjunction with Dr. Beata Wolucka, we had isolated and characterized p-D-Araf-1 -monophosphoryl decaprenol (Cso-P-Araf) [7] and proposed that it was the immediate donor of the Araf units of D-arabinan. In an important development, we chemically synthesized C,o-P-['4C]Araf and demonstrated that it was incorporated into the polymerized watersoluble CSO-P-P-GlcNAc-Rha-(Gal) 31-(Araf) product [8] .
Our concepts based on this evidence of the mechanism of cell wall biosynthesis are contained in Figure 3 .
Structure and biosynthesis of lipoarabinomannan (LAM)
LAM is regarded by some as the 'lipopolysaccharide of mycobacteria', a virulence factor, a major immunomodulator, a key ligand in phagocytosis. Thus disruption of its synthesis, although not lethal, would be expected to ameli-orate pathogenesis. Over years of effort, we have defined its full structure [9] and defined the entities within the molecule responsible for such functions as potent antigenicity, role in phagocytosis, inhibition of interferon y activation of T-cells, capacity to be presented to CD1-restricted T-cells, etc. It is composed of a tetrapartite structure, consisting of a phosphatidylinositol anchor, a mannan core (linear a 1 +blinked backbone; copious a 1 +Z branches), a mostly linear arabinan with little internal branching and with a 1 +Z-linked short manno-oligosaccharide 'caps', which are apparently involved in phagocytosis through their interaction with mannose receptors.
Besides the structures, we have also partially defined the biosynthesis of LAM, more specifically LM, i.e. the lipomannan core. It takes place in mycobacterial membranes as shown in Scheme 1. Thus we have developed assays that are suitable for conversion into screens in order to search for inhibitors of LM/LAM synthesis. 
Action of ethambutol (EMB): specifically directed to the a I -+3-linked arabinosyl-transferases of mycobacterial cell walls
Recently, we revisited the question of the effects of EMB on mycobacteria and concluded that it is primarily on polymerization steps in the biosynthesis of the arabinan component of cell wall AG [lo] . Inhibition of the synthesis of the arabinan of LAM occurred later, and thus, in the cases of AG and LAM, the polymerization of D-Araf apparently involves separate pathways/ enzymes. Although the synthesis of these arabinans was normal in an EMB-resistant isogeneic Decaprenyl-P (C, -P)+GDP-Man -.C,-P-Man
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PIMan2+ CSO-P-Man + PIMan, 4 PIMan4+ + PlMan + PIMan20 -+ -+ LM LM+Cso-P-An+ +LAM I92 strain, the addition of EMB to the resistant strain resulted in partial inhibition of the synthesis of the arabinan of LAM and the emergence of novel truncated forms of LAM, indicating only partial susceptibility of the resistant gene(s) and providing new intermediates in the LAM-biosynthetic sequence. A consequence of inhibition of AG arabinan biosynthesis was the lack of new sites for mycolate attachment and thus the channelling of mycolate residues into a variety of free lipids which then accumulated. The primary biochemical effects on EMB can be explained by postulating separate AG and LAM pathways catalysed by a variety of extramembranous arabinosyltransferases with variable degrees of sensitivity to EMB.
More recently, we have extended this reasoning further and have concluded that the primary effect of EMB is on the a1+3-arabinosyltransferases and that the drug has only a secondary effect on the M 1 -4 and other arabinosyltransferases. Hence the primary lethal effect is on the AG, not LAM, since AG, but not LAM, has extensive internal 3-linked branches.
These biochemical studies have been supported by genetic analysis of the emb region from M. avium and M. tuberculosis that results in EMB resistance when it is expressed in a susceptible M. smegmatis host on a multicopy vector [ 113. DNA-sequencing studies indicate that the emb region contains three open reading frames designated embR, embA and embB. The sequence of embR indicates a regulatory region. EmbA and embB both encode large (greater than 100 kDa) similar proteins, each with evidence of eight to ten transmembrane loops [ll] . M. smegmatis mc2155 was electroporated with pAEB148 (containing embR, embA and embB), pAEB109 (containing only embA and embB) or the cloning vector pMD31, and cell-free extracts were assayed for inhibition of arabinosyltransferase activity by EMB. Dose-response curves using -hereasing concentrations of EMB from 2.5 to 50
,ug/ml show that maximal inhibition is achieved at concentrations greater than or equal to 15 pglml. The vector control is inhibited 70-75%, indicating that this basic assay supports the activity of EMB-insensitive as well as EMB-sensitive arabinosyltransferase activities. In contrast, extracts from pAEB 148-and pAEB 109-containing cells are inhibited 30-35% and 55-60% respectively. These results indicate that the intact emb region is associated with significant EMB-resistant arabinosyltransferase activity and suggest that embR is required for maximum resistance. Thus far, there is strong biochemical evidence that embA and embB encode the cellular target for EMB, the arabinosyltransferase (s) and, specifically, the a1 +3-arabinosyltransferases required for cell wall arabinan biosynthesis.
Mycolic acid synthesis: the site of action of isoniazid (INH) and the focus of multiple drug action
INH, which is highly active against M. tuberculosis and is probably the most widely used antituberculosis agent, has been the subject of much research. Recently, Jacobs and colleagues [ 12,131 isolated a novel gene product, InhA, which, through point mutations within the inhA gene and in the 5'-regulatory region, were found to confer resistance to both INH and ethionamide among clinical isolates. The InhA protein has now been shown to catalyse the NADH-specific reduction of medium-chain (C12-C24) 2-transenoyl-acyl carrier protein (ACP) intermediates involved in fatty acid elongation consistent with its involvement in the early stages of mycolic acid biosynthesis. This observation has generated interest in the biosynthesis of mycolic acids and its exploitation as a target(s) for new drug development.
The extensive work of Bloch and colleagues [14, 15] demonstrated that M. smegmatis is unique in that it possesses both the multifunctional mycobacterial fatty acid synthase (FAS)-I and the monofunctional mycobacterial polypeptide FAS-I1 systems. The primary products produced by the de novo FAS-I system were c 1 6 -c 1 8 and c 2 4 -c 2 6 fatty acyl-CoA derivatives, and the distribution of these products was bimodal and influenced by the presence of the mycobacterial 6-0-methylglucose-and 3-O-methylmannosecontaining polysaccharides. The type-I complex appears to have limited elongation capacity and is apparently not capable of extending fatty acids to the meromycolate level. The ACP-requiring FAS-I1 system was unique in that it was regarded as an 'elongation mechanism', whereby mycobacteria would primarily elongate c l 6 fatty acid primers to produce C24-C30 fatty acyl-ACPs, but again apparently not to the meromycolate level. Thus it appears that the synthesis of mycolates, or at least meromycolates, requires a separate synthase.
More recently, a particulate cell-free system of Mycobacterium aurum and M. smegmatis was developed that allowed the synthesis of mycolic Volume 25 acids from acetate rather than malonate and also from a CZ4:,A5 fatty acid intermediate [16, 17] . Using this system, we have demonstrated that thiolactomycin (TLM) inhibits both fatty acid (80%) and mycolic acid (86%) synthesis [18] . Moreover, synthesis of the shorter-chain a'-mycolates of M. smegmatis was not inhibited by TLM, whereas the characteristic longer-chain a-and epoxy-mycolates were almost completely inhibited at 75 pg/ml. Cell-free extracts of M.
smegmatis demonstrated that TLM in a dosedependent manner specifically inhibited the mycobacterial ACP-dependent FAS-I1 and not the mycobacterial multifunctional FAS-I. In vivo and in vitro data and the precedence of TLM resistance in E. coli suggest that two distinct TLM targets exist in mycobacteria, which are presumably P-ketoacyl-ACP synthases involved in FAS-I1 and the elongation steps leading to the synthesis of the a-and oxygenated mycolates of mycobacteria.
This work on TLM has allowed us to extend the work of Quemard and colleagues [13] suggesting that InhA, which is a long-chain (C1Z-Cz4) enoyl-ACP-dependent reductase, is part of the type-I1 ACP-dependent FAS-I1 system described by Bloch and colleagues. In our hands, INH in the presence of catalase/peroxidase activity and crude cell-free extracts of M. smegmatis failed to inhibit the ACP-dependent FAS-I1 system described by Bloch. The relevance of this observation to the present study becomes more obvious when considering the mode of action of TLM in the context of FAS-I1 and the synthases responsible for mycolate synthesis. If the ACP-dependent FAS-I1 system is involved in the early stages of mycolic acid synthesis as suggested, then TLM, which has now been shown to be a potent inhibitor of this system, would lead to a subsequent inhibition of all types of mycolic acids. However, this is not the case, since the a'-mycolates of M. smegmatis mc'155 are still synthesized, and TLM exhibits selective inhibition of the ACP-dependent FAS-I1 system and an elongation step specific to the synthesis of the long-chain a-and oxygenated mycolates of M. smegmatis and M. tuberculosis. This suggests an alternative mechanism, presumably involving a membrane-bound ACP-dependent FAS-I1 system, of which InhA is a part, which performs de novo synthesis and provides fatty acid primers used exclusively for mycolate synthesis. In addition, this specialized type-I1 mycolic acid synthase is particulate in nature, as demonstrated by its location within cell wall extracts, which is clearly distinct from the soluble ACP-dependent FAS-I1 system. Indeed, the addition of INH to the cell wall extracts in the presence of catalase/peroxidase activity results in strong inhibition ( > 85%) of mycolate synthesis in M. smegmatis at 100
Fglrnl.
Thus these data demonstrate that mycolic acid synthesis is a powerful target for the development of new antagonists and for explaining the action of existing inhibitors.
Prospects for the exploitation of this knowledge for the discovery of new drugs against tuberculosis
Several large pharmaceutical companies have realized the potential of converting the basic information described above into screens to allow the identification of new drugs against tuberculosis based on the principle of disruption of cell wall biogenesis. Foremost among these companies is GlaxoWellcome in the U.K. and SmithKline Beecham in the U.K./U.S. We are working with these companies at various levels in an effort to convert this basic information into practical use. 
Introduction
Fungi and plant cells have a wall. T h e fungal cell wall has similar functions to that of the plant: physical protection, osmotic stability, enzyme support, selective permeability barrier, binding to cells or inert material. T h e main difference between the plant and fungal cell wall is its gross composition [ 1-31. Cellulose and hemicellulose are the main components of the plant cell wall whereas the main fungal components are glucan in the a and p configuration with 1-3 and 1-6 but never 1-4 linkages. Oomycetes and Hyphochytriomycetes, which were considered in the past as the only fungal groups having a celluloserich wall, have now been removed from the fungal kingdom and included in the algal kingdom in the Chromista [4] . T h e other major structural polysaccharide component of the fungal cell wall, also found in arthropods, is chitin. Proteins are also present in the cell wall mainly associated with hetero-or homo-polymers of mannans. Recent studies have pointed out the role of proteins in the dynamics of fungal cell wall construction. We present here our current knowledge of the organization and crosslinking of the surface and constitutive protein and polysaccharide wall molecules with some insight into their possible role during hostfungus interactions in a medical background Abbreviation used: GPI, glycosylphosphatidylinositol.
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using the yeast Candida and the filamentous fungus Aspergillus as models.
Surface molecules
( I ) The crawling and sticky proteins (a) Hydrophobins and rodlets T h e discovery more than 30 years ago of rodlet fascicles on the surface of aerial conidia was coincident with the development of electronmicroscopic freeze-etching techniques. T h e role of this rodlet layer in the hydrophobicity of conidia was also suggested at the same time, since its removal or masking by mucus was found to make the conidia hydrophilic [S] . However, the chemical composition of this layer remained controversial until the genes coding for the small secreted hydrophobic proteins (hydrophobins) responsible for rodlet configuration were identified in the 1980s by Wessels' group while screening for genes differentially expressed during sporulation [6, 7] . More than 20 genes coding for hydrophobins have been cloned from fungi pathogenic for humans, insects and plants ( [8-101 as examples) . All type-I hydrophobins found on the spore surface share the same characteristics: they are about 13 f 3 kDa with similar hydropathy patterns and the conserved presence of eight similarly spaced cysteine residues [l] . These hydrophobins form SDSinsoluble complexes in the aerial fungal propagules [ll] . T h e insolubility of these hydropho-
